Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight

Executive Summary

Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.

Advertisement

Related Content

Rx Spending Stands Out In CMS Projections – As Slowing Down
Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority
Rx Cost Containment At CareFirst Driven By Physician Incentives
Price Concessions By Manufacturers To Payers Rose Sharply In 2015
Rx Spending Growth Won’t Exceed 8% In Coming Years – Express Scripts
Medicare Value-Pricing Options Vary Widely In Part B Payment Experiment
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid
U.S. Drug Spending Will Increase 7.6% in 2015, Including PCSK9 Costs – CMS

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel